Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen

Therapeutic Drug Monitoring

Volumn 29, Issue 5, 2007, Pages 566-570

  Lowe, Selwyn H ^a,b,d   Van Leeuwen, Elisabeth ^a   Droste, Jacqueline A H ^c   Van Der Veen, Fulco ^a   Reiss, Peter ^a   Lange, Joep M A ^a,b   Burger, David M ^c   Repping, Sjoerd ^a   Prins, Jan M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b International Antiviral Therapy Evaluation Center (IATEC)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Didanosine; Drug concentration; HIV; Semen; Tenofovir

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; TENOFOVIR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SEMINAL PLASMA; SPERM; SPERMATOZOON MOTILITY; WORLD HEALTH ORGANIZATION;

ADENINE; ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; SEMEN; SPERM MOTILITY; SPERMATOZOA;

EID: 34848858582     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31811fef29     Document Type: Article

References (20)

1. Lowe SH, Sankatsing SU, Repping S, et al. Is the male genital tract really a sanctuary site for HIV? Arguments that it is not. AIDS. 2004;18:1353-1362.
2. Taylor S, Boffito M, Vernazza PL. Antiretroviral therapy to reduce the sexual transmission of HIV. J HIV Ther. 2003;8:55-66.
3. Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry. 2003;42:14711-14719.
4. Cruciani M, Liuzzi G, Chirianni A, et al. Penetration of didanosine in semen of HIV-1 infected men. J Antimicrob Chemother. 2006;57:1244-1247.
5. Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS. 2004;18:1958-1961.
6. Pecora Fulco P, Kirian MA. Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother. 2003;37:1325-1328.
7. Pruvost A, Negredo E, Benech H, et al. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2005;49:1907-1914.
8. World Health Organization (WHO). WHO Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucus Interaction, 3rd ed. Cambridge, UK: Cambridge University Press; 1992.
9. Verweij-van Wissen CPWGM, Aarnoutse RE, Burger DM. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J Chromatogr B. 2005;816:121-129.
10. la Porte C, Verweij-van Wissen C, van Ewijk N, et al. Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers. J Clin Pharmacol. 2005;45:211-218.
11. Droste JA, Verweij-Van Wissen CP, Kearney BP, et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2005;49:680-684.
12. Holland DT, DiFrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS Clinical Trials Group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824-831.
13. Taylor S, Back DJ, Drake SM, et al. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother. 2001;48:351-354.
14. Van Praag RM, Repping S, de Vries JW, et al. Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma. Antimicrob Agents Chemother. 2001;45:2902-2907.
15. Taylor S, van Heeswijk RPG, Hoetelmans RMW, et al. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1 infected men. AIDS. 2000;14:1979-1984.
16. Dondero F, Rossi T, D'Offizi G, et al. Semen analysis in HIV seropositive men and in subjects at high risk for HIV infection. Hum Reprod. 1996;11:765-768.
17. Krieger JN, Coombs RW, Collier AC et al. Fertility parameters in men infected with human immunodeficiency virus. J Infect Dis. 1991;164:464-469.
18. Politch JA, Mayer KH, Abbott AF, et al. The effects of disease progression and zidovudine therapy on semen quality in human immunodeficiency virus type I seropositive men. Fertil Steril. 1994;61:922-928.
19. van Leeuwen E, Cornelissen M, de Vries JW, et al. Semen parameters of a semen donor before and after infection with human immunodeficiency virus type 1: case report. Hum Reprod. 2004;19:2845-2848.
20. Robbins WA, Witt KL, Haseman JK, et al. Antiretroviral therapy effects on genetic and morphologic end points in lymphocytes and sperm of men with human immunodeficiency virus infection. J Infect Dis. 2001;184:127-135.